Abstract | BACKGROUND: OBJECTIVE: This study's aim was to determine whether chronic eplerenone treatment protects against detrimental ventricular electrical remodeling and development of an arrhythmogenic substrate in a rapid ventricular pacing (RVP)-induced heart failure model. METHODS: Dogs were assigned randomly to oral placebo or eplerenone treatment and divided into 4 groups: 2 sham-operated (no RVP) and 2 RVP groups. After 5 weeks of no RVP or RVP along with concurrent placebo or eplerenone treatment, dogs underwent echocardiographic assessments of systolic function and chamber size and electrophysiologic measurements of ventricular repolarization, refractoriness, conduction, tachyarrhythmia inducibility, and myocardial activation delays after premature stimulation. RESULTS: CONCLUSIONS:
|
Authors | Bruce S Stambler, Kenneth R Laurita, Sunil C Shroff, Gregory Hoeker, Nichole L Martovitz |
Journal | Heart rhythm
(Heart Rhythm)
Vol. 6
Issue 6
Pg. 776-83
(Jun 2009)
ISSN: 1556-3871 [Electronic] United States |
PMID | 19427273
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Mineralocorticoid Receptor Antagonists
- Spironolactone
- Eplerenone
|
Topics |
- Animals
- Disease Models, Animal
- Dogs
- Electrocardiography
- Eplerenone
- Heart Failure
(complications, physiopathology)
- Mineralocorticoid Receptor Antagonists
(pharmacology)
- Spironolactone
(analogs & derivatives, pharmacology)
- Tachycardia, Ventricular
(etiology, physiopathology)
- Ventricular Remodeling
(drug effects)
|